REFERENCES
- Rouzioux C, Hubert J, Burgard M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are pre-dictive of disease progression independently of HIV-1 RNA levels and CD4+ cell counts. J Infect Dis. 2005;192:46–55.
- Maldarelli F, Palmer S, King M, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pre-therapy viraemia. PLoS Pathogens. 2007;3:484–488.
- Viard J, Burgard M, Hubert JB, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS. 2004;18:45–49.
- Doyle T, Geretti AM. Low-level viraemia on HAART: signifi-cance and management. Cum Opin Infect Dis. 2012;25:17–25.
- Rong L, Perelson AS. Modeling latently infected cell acti-vation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput BioL 2009;5:e1000533.
- Piketty C, Weiss L, Assoumou L, et al. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, indepen-dently of the CD4 nadir. J Med Virol. 2010; 82:1819–1828.
- Arribas JR, Clumeck N, Nelson M, Hill A, van Delft Y, Moecklinghoff C. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load <50 HIV-1 RNA cop-ies/mL at baseline. HIV Med. 2012;13:398–405.
- Katlama C, Valentin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label non-inferiority trial, MONOI-ANRS 136. AIDS. 2010;24:2365–2374.
- Guaraldi G, Zona S, Cossarizza A, et al. Impact of switch-ing to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in virologically suppressed HIV-infected adults. The MONARCH random-ized controlled trial. In: Program and abstracts of the Euro-pean AIDS Conference; October 2011; Belgrade, Serbia. Abstract PE7.5/4.
- Avettand-Fenoel V, Chaix ML, Blanche S, et al. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive moth-ers treated in HAART area (ANRS CO 01). J Med Virol. 2009;81:217–223.
- Avettand-Fenoel V, Flandre P, Chaix M, et al. Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial. J Antimicrob Chemother 2010;65:1005–1007.
- Boulassel MR, Chomont N, Pai NP, Gilmore N, Sékaly RP, Routy JP. CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy. J Clin Virol. 2012;53: 29–32.
- Marcelin A, Lambert-Niclot S, Peytavin G, et al. Baseline HIV RNA ultrasensitive assay and viral DNA predict rise in plasma viral load in patients of MONOI-ANRS 136 trial. In: Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; February 2011; Boston, Massachusetts. Abstract 533.
- Lambert-Niclot S, Flandre P, Valentin M-A, et al. Similar evolution of cellular HIV-1 DNA level in rarunavir/ritonavir monotherapy versus triple therapy in MONOI —ANRS136 trial over 96 weeks. PLoS ONE. 2012;7: e41390.
- Pulido F, Pérez-Valero I, Delgado R, et al. Risk factors for loss of virological suppression in patients receiving Iopine-vir/ritonavir monotherapy for maintenance of HIV suppres-sion. Antiviral Ther 2009;14:195–201.
- Chun TW, Murray D, Justement JS, et al. Relationship between residual plasma viremia and the size of HIV pro-viral DNA reservoirs in infected individuals receiving effec-tive antiretroviral therapy. J Infect Dis. 2011;204:135–138.
- UK Medical Research Council. A randomised controlled trial of a strategy of switching to boosted protease inhibitor monotherapy versus continuing combination antiretroviral therapy for the long-term management of HIV-1 infected patients who have achieved sustained virological sup-pression on highly-active antiretroviral therapy C PIVOT trial. http://www.controlled-trials.com/ISRCTN04857074. Accessed May 13, 2011.